References
- Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–2293.
- Martens P, Nijst P, Verbrugge FH, et al. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018;73(2):115–123.
- Carbone L, Buzkova P, Fink HA, et al. Hip fractures and heart failure: findings from the cardiovascular health study. Eur Heart J. 2010;31(1):77–84.
- Frost RJ, Sonne C, Wehr U, et al. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol. 2007;156(3):309–314.
- Lyons KJ, Majumdar SR, Ezekowitz JA. The unrecognized burden of osteoporosis-related vertebral fractures in patients with heart failure. Circ Heart Fail. 2011;4(4):419–424.
- Jankowska EA, Jakubaszko J, Cwynar A, et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail. 2009;11(1):28–38.
- Terrovitis J, Zotos P, Kaldara E, et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail. 2012;14(3):326–332.
- Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. Faseb J. 2008;22(7):2465–2475.
- Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–469.
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
- Kanis JA, Johnell O, Oden A, et al. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone. 2002;30(1):251–258.
- Law PH, Sun Y, Bhattacharya SK, et al. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol. 2005;46(1):142–146.
- Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137–155.
- Schlienger RG, Kraenzlin ME, Jick SS, et al. Use of beta-blockers and risk of fractures. Jama. 2004;292(11):1326–1332.
- Wiens M, Etminan M, Gill SS, et al. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med. 2006;260(4):350–362.
- Kanis JA, Cooper C, Rizzoli R, et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int. 2019;104(3):235–238.
- Page RL, O’Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):e32–e69.